🇺🇸 FDA
Patent

US 7524880

Crystalline form of a substituted pyrrolidine compound

granted A61PA61P11/06A61P11/08

Quick answer

US patent 7524880 (Crystalline form of a substituted pyrrolidine compound) held by Theravance, Inc. expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61P, A61P11/06, A61P11/08